These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33156982)

  • 41. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses.
    Halpin DMG; Birk R; Brealey N; Criner GJ; Dransfield MT; Hilton E; Lomas DA; Zhu CQ; Lipson DA
    ERJ Open Res; 2018 Apr; 4(2):. PubMed ID: 29750142
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system.
    Balmaceda C; Espinoza MA; Abbott T; Peters A
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):743-751. PubMed ID: 35176212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK.
    Kendall R; Martin AA; Shah D; Shukla S; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1815-1825. PubMed ID: 37636901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol or Other Triple Therapies in Japan: A Real-World Healthcare Claims Database Study (MITOS-AURA).
    Takahashi K; Makita N; Castañeda-Sanabria J; Argoubi R; Nowacki G; Issa S; Matsumoto I; Yoshida Y; Müllerová H
    Adv Ther; 2024 Dec; 41(12):4518-4536. PubMed ID: 39412626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient and Clinical Demographics of New Users to Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.
    Wu B; Mannino D; Mu G; Stiegler M; Bogart M
    Pulm Ther; 2022 Jun; 8(2):195-208. PubMed ID: 35467260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US.
    Bogart M; Germain G; Laliberté F; Mahendran M; Duh MS; DiRocco K; Noorduyn SG; Paczkowski R; Balkissoon R
    J Asthma Allergy; 2023; 16():1309-1322. PubMed ID: 38058516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial.
    Paly VF; Vallejo-Aparicio LA; Martin A; Izquierdo JL; Riesco JA; Soler-Cataluña JJ; Abreu C; Biswas C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():3097-3109. PubMed ID: 36561129
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
    Yang S; Lee LA; Sule N; Fowler A; Peachey G
    Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial.
    Beeh KM; Scheithe K; Schmutzler H; Krüger S
    Int J Chron Obstruct Pulmon Dis; 2024; 19():205-216. PubMed ID: 38249826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - The IMPACT trial.
    Risebrough NA; Mursleen S; Ndirangu K; Shah D; Martin A; Schroeder M; Ismaila AS
    Respir Med; 2024 Sep; 231():107694. PubMed ID: 38844004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
    Mehta R; Farrell C; Hayes S; Birk R; Okour M; Lipson DA
    Clin Pharmacokinet; 2020 Jan; 59(1):67-79. PubMed ID: 31321713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
    Halpin DMG; Kendall R; Shukla S; Martin A; Shah D; Midwinter D; Beeh KM; Kocks JWH; Jones PW; Compton C; Risebrough NA; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2745-2755. PubMed ID: 36317185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
    Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial.
    Gabrio A; Gunsoy NB; Baio G; Martin A; Paly VF; Risebrough N; Halpin DMG; Singh D; Wise RA; Han MK; Martinez FJ; Criner GJ; Martin N; Lipson DA; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1633-1642. PubMed ID: 35915738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
    Maleki-Yazdi MR; Singh D; Anzueto A; Tombs L; Fahy WA; Naya I
    Adv Ther; 2017 Jan; 33(12):2188-2199. PubMed ID: 27796912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
    Lipson DA; Barnhart F; Brealey N; Brooks J; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Martinez FJ; Singh D; Tabberer M; Wise RA; Pascoe SJ;
    N Engl J Med; 2018 May; 378(18):1671-1680. PubMed ID: 29668352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan.
    Umeda A; Shimada H; Yamane T; Mochizuki T; Inoue Y; Tsushima K; Miyagawa K; Mochida A; Takeda H; Okada Y; Masaki K; Matsusaka M; Fukunaga K
    Front Physiol; 2023; 14():1131949. PubMed ID: 37179838
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.